Amivantamab (JNJ-61186372) is a Human EGFR-MET Bispecific Antibody

Epidermal growth factor (EGF) is a protein that stimulates cell proliferation, differentiation, and survival by binding to its receptor EGFR. Additionally, It exists in platelets, urine, saliva, milk, tears, and blood plasma. The mesenchymal-epithelial transition (MET) is the reverse process of the epithelial-mesenchymal transition (EMT). Moreover, MET involves morphological...

YL-939, a Potent Ferroptosis Inhibitor, Acts by Targeting the PHB2/Ferritin/Iron Axis

Ferroptosis is a form of programmed cell death mediated by iron-dependent lipid peroxidation and was first proposed by Brent Stockwell and Scott J. Dixon in 2012. It differs genetically and biochemically from other forms of regulated cell death, such as apoptosis, uncontrolled necrosis, and necrotizing apoptosis. The main features...

Bapotulimab (BAY-1905254) is an IgG2 Antibody Targeting ILDR2

Immunoglobulin-like domain containing receptor 2 (ILDR2) is a B7-like protein that belongs to the B7 family of immunomodulatory receptors. It can induce an immunosuppressive effect on T-cell responses. ILDR2 is a negative regulator for T cells. Besides, ILDR2 is expressed in immune cells and in immune-privileged and inflamed tissues....

YX-2-107, a PROTAC, is a Selective CDK6 Degrader

Ph+ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia) is a rare subtype of leukemia characterized by the abnormal formation of the Philadelphia chromosome, which occurs when pieces of chromosomes 9 and 22 switch with each other. The incidence of Ph+ ALL increases with age, and occurs in up to 50 %...

SIAIS100 is a Potent BCR-ABL PROTAC Degrader

Chronic myeloid leukemia (CML) is a kind of myeloproliferative neoplasms (MPN). It is characterized by the proliferation of a pluripotential stem cell that can differentiate along the granulocytic lineage. In terms of mechanism, it is consistently related to the BCR-ABL1 fusion gene. CML is typically relevant to a balanced...

Benufutamab (GEN1029) is a DR5-Specific Agonistic Antibody for Solid Tumor Research

Death receptor 5 (DR5), also known as TRAIL receptor 2 (TRAILR2) and TNFR superfamily member 10B (TNFRSF10B), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Triggering of these receptors via TRAIL or agonistic antibodies selectively induced apoptosis in malignant cells derived from...